The BioFire® COVID-19 Test is a nested multiplexed RT-PCR test intended for the qualitative detection of SARS-CoV-2 RNA in upper respiratory (nasopharyngeal, oropharyngeal, mid-turbinate nasal, or anterior nasal swabs), lower respiratory (sputum-like or BAL-like), and saliva specimens from individuals suspected of COVID-19 by their healthcare provider.

US FDA – BioFire COVID-19 Test v1.1
|
![]() |
| US FDA Documentation – EUA
The EUA (Emergency Use Authorization) for the BioFire COVID-19 Test enables CLIA moderate and high complexity laboratories to conduct a PCR test for SARS-CoV-2 in-house, providing results in approximately one hour. |
|||||
| Date of Issuance | Letter of Authorization | Fact Sheets and Labeling | Determination and Declarations | ||
| Issued: March 23, 2020
Updated: May 24, 2022 EUA No: EUA200044 |
Authorization Letter (Link to FDA.gov) | Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Coronavirus (COVID-19) (Link to FDA.gov) |
|||
|
|||||
Kits Available |
|||||||||
![]() |
![]() |
||||||||
Instructions for Use and Quick Guides are found in the table above |
|
||||||||
| Download the BioFire COVID-19 Test v1.1 Information Sheet |
Software
|
||||||||
|
Reporting |
| Please report adverse events associated with the use of the BioFire COVID-19 Test here: BioFire COVID-19 Test Report Form |